Jobs
View more job listings or post a job
Bioduro-Sundia Associate Director/Director in Laboratory Animal and Exploratory Toxicology
Variant Bio (Senior) Scientist - DMPK
Alturas Analytics Scientist 1
University of California, Davis TOXICOLOGY ANALYTICAL CHEMIST (STAFF RESEARCH ASSOCIATE 3)
University of California, Davis CALIFORNIA ANIMAL HEALTH AND FOOD SAFETY LABORATORY - TOXICOLOGY LAB RESEARCH SUPERVISOR/GROUP LEADER
Eli Lilly and Company R-39973 Scientific Director ADME - Novel Modalities (Open)
FibroGen Director DMPK
Applied BioMath Technical Marketing Specialist
Horizon Therapeutics Director, Bioanalytical Sciences
Exelixis Principal Scientist - DMPK
Post a job

Seminar luncheon

Developing Relevant Human Neural In Vitro Assays for CNS Safety Assessment and Drug Discovery: Challenges and Perspectives


Speakers: Jonathan Davila PhD., CEO / Co-Founder, NeuCyte Inc.
Organizers:
Date: 2017-07-28
Time: 11:00-13:30 Pacific Time
Registration fee: (USD): Food: $0.
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (1)Cellular Dynamics Intl
Vendor show vendors registered to date: (5)Agilent; BioLegend; Cyprotex; JL Powers & Co; Thermo Fisher Scientific, SID
Registration: http://www.PBSS.org
Registration deadline:2017-07-26  (it will close sooner if the seating cap is reached)

About the Topic

High attrition rates of novel CNS drugs indicate that current preclinical testing is largely insufficient to support development of urgently needed therapies for millions of patients. iPSC technology and rapidly improving methods to generate functional human tissues offer new opportunities to develop novel disease relevant cell-based assays. This approach comes with high expectations but also presents many challenges. NeuCyte develops human neural in vitro platforms uniquely suited for assessing relevant complex  electrophysiology readouts allowing for more reliable prediction of drug efficacy, CNS safety, and identification of neurotoxicity. In this presentation, we will provide an overview of critical considerations that need to be taken when developing human iPSC derived neural in vitro assays. 


2024-03-07, [In-Person] Project/Program Management Elevating Drug Development
2024-03-15, [Free Online] Oncology Business Development and Partnering: perspectives and advice from buyers
2024-03-28, [In-Person] Antibody-Drug Conjugates from Discovery to Development: Chemistry, Engineering, Characterization, CMC, PK/Tox, Clinical design and Intellectual Property
2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
2024-09-10, [In-Person] Translational PK/PD considerations for Novel Modalities
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
┬ęPharmaceutical & BioScience Society, International; Last Modified: 2/29/2024; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Lena Biosciences Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
Submit a Text Ad